TY  - JOUR
AU  - de-la-Cruz-Ojeda, Patricia
AU  - Schmid, Tobias
AU  - Boix, Loreto
AU  - Moreno, Manuela
AU  - Sapena, Víctor
AU  - Praena-Fernandez, Juan M
AU  - Castell, Francisco J
AU  - Falcon-Perez, Juan Manuel
AU  - Reig, Maria
AU  - Brüne, Bernhard
AU  - Gomez-Bravo, Miguel A
AU  - Giraldez, Alvaro
AU  - Bruix, Jordi
AU  - Ferrer, Maria T
AU  - Muntane, Jordi
PY  - 2022
DO  - 10.3390/cells11172673
UR  - http://hdl.handle.net/10668/20935
T2  - Cells
AB  - Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid...
LA  - en
PB  - MDPI AG
KW  - Sorafenib
KW  - extracellular vesicle
KW  - hepatocellular carcinoma
KW  - liquid biopsy
KW  - miRNA
KW  - Biomarkers
KW  - Carcinoma, Hepatocellular
KW  - Humans
KW  - Liver Neoplasms
KW  - MicroRNAs
KW  - Sorafenib
TI  - miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
TY  - research article
VL  - 11
ER  -